Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004104 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004104 is a Phase 2 study that has completed, run by NYU Langone Health.
The verdict
NCT00004104, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response and kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Interferon alfa-2b may interfere with the growth of tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of vaccine therapy plus interleukin-2 with or without interferon alfa-2b in treating patients who have stage III melanoma.
Interventions
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL liposomal interleukin-2
- BIOLOGICAL polyvalent melanoma vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004104
The ClinicalTrials.gov registry entry for NCT00004104 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which recombinant interferon alfa is the first listed.
NCT00004104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004104 about?
NCT00004104 is a clinical study titled "Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma". RATIONALE: Vaccines may make the body build an immune response and kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Interferon alfa-2b may interfere with the growth of tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of vacc...
What is the current status of trial NCT00004104?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-06.
What interventions are being tested in trial NCT00004104?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL), liposomal interleukin-2 (BIOLOGICAL), polyvalent melanoma vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004104?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.